Literature DB >> 36210416

Comparative Analysis of the Pharmacological Activity of Bis(3,5-di-Tert-Butyl-4-Hydroxyphenylthiolate)Dimethylol in Different Modes of Administration on a Mouse Model of Melanoma B16 Tumor Growth.

M A Dodokhova1, I M Kotieva2, A V Safronenko2, M S Alkhusein-Kulyaginova2, N V Sukhorukova2, V M Kotieva2, E M Kotieva2, S I Starostin2, D B Shpakovsky3, E A Nikitin3, E R Milaeva3.   

Abstract

We performed a comparative analysis of the pharmacological activity of the hybrid organotin compound bis(3,5-di-tert-butyl-4-hydroxyphenylthiolate)dimethylol (Me-3) administered in different modes to mice with transplanted melanoma B16 to identify the most effective dosage regimen. Three modes of administration were used: preventive (before transplantation of tumor cells), classical according to Z. P. Sof'ina (48 h after transplantation of tumor cells), and delayed (7 days after transplantation of tumor cells, after formation of nodules of the primary tumor node). Compound Me-3 was administered at a total dose of 375 mg/kg intraperitoneally once a day for 5 days. The classical mode of administration was identified as the most effective, which indicates the preventive antimetastatic activity of Me-3 on the model of the transplanted mouse tumor melanoma B16.
© 2022. Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  melanoma B16; metastasis; modes of administrations; organotin compounds

Mesh:

Year:  2022        PMID: 36210416     DOI: 10.1007/s10517-022-05599-9

Source DB:  PubMed          Journal:  Bull Exp Biol Med        ISSN: 0007-4888            Impact factor:   0.737


  2 in total

1.  Systematic heterogenization for better reproducibility in animal experimentation.

Authors:  S Helene Richter
Journal:  Lab Anim (NY)       Date:  2017-08-31       Impact factor: 12.625

Review 2.  The benefits of ascorbate to protect healthy cells in the prevention and treatment of oncological diseases.

Authors:  Pavel Klener; Matthew Scott Alexander; Joseph John Cullen; Vera Stejskal; Jiri Sliva; Lucie Kotlarova; Pavel Kostiuk; Zdenek Prochazka; Marta Kucerova
Journal:  J Appl Biomed       Date:  2020-02-19       Impact factor: 1.797

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.